lamotrigine and Depression studies

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

Excerpt	Relevance	Reference
"Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines."	9.27	Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). ( Gardiner, A; Geddes, JR; Goodwin, GM; Mayer, S; Rendell, J; Simon, J, 2018)
"The active dose of methylene blue significantly improved symptoms of depression both on the Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression (P = 0."	9.24	Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. ( Alda, M; Blagdon, R; Dursun, S; Garnham, J; Hajek, T; MacLellan, S; MacQueen, G; McKinnon, M; Nair, C; O'Donovan, C, 2017)
" Lamotrigine, an anticonvulsant which decreases presynaptic glutamate release, has been shown to be effective in the depressive phase of bipolar disorder (BD-D); however, only 40-50% of patients have a full response."	9.16	Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. ( Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012)
" Patients who did not meet the criteria for a bimodal response after up to 16-weeks of open-label treatment with lithium plus divalproex, as measured by MADRS (Montgomery-Asberg Depression Rating Scale) ≤ 19, YMRS ( Young Mania Rating Scale) ≤ 12 and GAF (Global Assessment of Functioning) = 51 for 4 weeks, were randomized to a 12- week, double-blind addition of lamotrigine or placebo to lithium plus divalproex."	9.14	Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010)
"In this investigation, the effects of lamotrigine versus placebo on depressive symptoms in patients with epilepsy were prospectively assessed."	9.12	Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. ( Ettinger, AB; Hammer, AE; Kustra, RP, 2007)
"This open-label study evaluated the antidepressant qualities of lamotrigine (LTG) in people with epilepsy."	9.12	Lamotrigine in patients with epilepsy and comorbid depressive symptoms. ( Barry, JJ; Fakhoury, TA; Hammer, AE; Mitchell Miller, J; Vuong, A, 2007)
"Whether patients with adult bipolar disorder (BD) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully."	9.01	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. ( Esumi, S; Hashimoto, R; Hashimoto, Y; Hatano, M; Iwata, N; Kato, M; Kishi, T; Matsuda, Y; Matsui, Y; Mishima, K; Miyake, N; Nomura, I; Okuya, M; Oya, K; Sakuma, K; Watanabe, N, 2019)
" Lamotrigine is currently considered at best only as second line augmentation for treatment-resistant unipolar depression while its clinical efficacy and safety profiles remain inconclusive."	9.01	Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. ( Chen, CH; Chiu, YH; Goh, KK; Lu, ML, 2019)
"To meta-analytically summarize lamotrigine's effectiveness and safety in unipolar and bipolar depression."	8.93	Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)
"Lamotrigine is used to treat bipolar depression despite inconsistent evidence."	8.02	Lamotrigine for acute bipolar depression: An exploratory item-level analysis. ( Balbuena, L; Li, H; Lodhi, RJ; Peters, EM; Zhang, Y, 2021)
" However, there were no associations between NAA/Cr, Glu/Cr, or Gln/Cr and either depression severity or lamotrigine treatment."	7.91	Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. ( Forester, BP; Harper, DG; Jensen, E; Mellen, EJ; Ravichandran, C; Silveri, M, 2019)
"Lamotrigine (LTG) has a good efficacy and tolerability as initial monotherapy for patients with newly diagnosed epilepsy (NDE)."	7.79	Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. ( Park, SP, 2013)
"Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy."	7.75	End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009)
"We describe a patient originally suffering from a depressive syndrome who developed Stevens-Johnson syndrome after 12 days of treatment with lamotrigine."	7.75	Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. ( Bertram, L; Grözinger, M; Liss, Y, 2009)
"We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram."	7.74	Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007)
"2 years) treated with the combination of lithium and lamotrigine were reviewed retrospectively for treatment response using the Clinical Global Impression-Bipolar Disorder-Improvement scale, divided into benefit for acute depressive symptoms, acute manic symptoms, and overall illness (including prophylaxis of mood episodes)."	7.73	Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. ( Berv, DA; Ghaemi, SN; Goodwin, FK; Klugman, J; Pardo, TB; Schrauwen, E; Shirzadi, AA, 2006)
"Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines."	5.27	Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). ( Gardiner, A; Geddes, JR; Goodwin, GM; Mayer, S; Rendell, J; Simon, J, 2018)
"The active dose of methylene blue significantly improved symptoms of depression both on the Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression (P = 0."	5.24	Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. ( Alda, M; Blagdon, R; Dursun, S; Garnham, J; Hajek, T; MacLellan, S; MacQueen, G; McKinnon, M; Nair, C; O'Donovan, C, 2017)
"Ketamine is a rapid-acting antidepressant with proven efficacy as an add-on agent in unipolar and bipolar treatment-resistant depression."	5.22	Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review. ( Cubała, WJ; Jakuszkowiak-Wojten, K; Wiglusz, MS; Wilkowska, A, 2022)
" Lamotrigine, an anticonvulsant which decreases presynaptic glutamate release, has been shown to be effective in the depressive phase of bipolar disorder (BD-D); however, only 40-50% of patients have a full response."	5.16	Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. ( Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012)
" Patients who did not meet the criteria for a bimodal response after up to 16-weeks of open-label treatment with lithium plus divalproex, as measured by MADRS (Montgomery-Asberg Depression Rating Scale) ≤ 19, YMRS ( Young Mania Rating Scale) ≤ 12 and GAF (Global Assessment of Functioning) = 51 for 4 weeks, were randomized to a 12- week, double-blind addition of lamotrigine or placebo to lithium plus divalproex."	5.14	Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010)
"This review does not provide sufficient evidence to support levetiracetam, phenobarbital or lamotrigine for the treatment of epilepsy in people with Alzheimer's disease."	5.12	Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN, 2021)
"In this investigation, the effects of lamotrigine versus placebo on depressive symptoms in patients with epilepsy were prospectively assessed."	5.12	Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. ( Ettinger, AB; Hammer, AE; Kustra, RP, 2007)
"This open-label study evaluated the antidepressant qualities of lamotrigine (LTG) in people with epilepsy."	5.12	Lamotrigine in patients with epilepsy and comorbid depressive symptoms. ( Barry, JJ; Fakhoury, TA; Hammer, AE; Mitchell Miller, J; Vuong, A, 2007)
" Lamotrigine is currently considered at best only as second line augmentation for treatment-resistant unipolar depression while its clinical efficacy and safety profiles remain inconclusive."	5.01	Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. ( Chen, CH; Chiu, YH; Goh, KK; Lu, ML, 2019)
"Whether patients with adult bipolar disorder (BD) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully."	5.01	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. ( Esumi, S; Hashimoto, R; Hashimoto, Y; Hatano, M; Iwata, N; Kato, M; Kishi, T; Matsuda, Y; Matsui, Y; Mishima, K; Miyake, N; Nomura, I; Okuya, M; Oya, K; Sakuma, K; Watanabe, N, 2019)
"To meta-analytically summarize lamotrigine's effectiveness and safety in unipolar and bipolar depression."	4.93	Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)
" Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression."	4.90	Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014)
" The following keywords were searched: lamotrigine, psychiatric, mood disorders, depression, personality disorders, anxiety, schizophrenia, side effects, and rash."	4.89	Lamotrigine in psychiatric disorders. ( Altshuler, LL; Gitlin, MJ; Reid, JG, 2013)
"In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients."	4.12	Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022)
"Lamotrigine is used to treat bipolar depression despite inconsistent evidence."	4.02	Lamotrigine for acute bipolar depression: An exploratory item-level analysis. ( Balbuena, L; Li, H; Lodhi, RJ; Peters, EM; Zhang, Y, 2021)
"299 patients with uni- and bipolar depression treated with rTMS were selected for analysis in respect to intake of lithium, lamotrigine and valproic acid."	4.02	Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs. ( Abdelnaim, MA; Deppe, M; Hebel, T; Kreuzer, PM; Langguth, B; Mohonko, A; Poeppl, TB; Rupprecht, R; Schecklmann, M, 2021)
" However, there were no associations between NAA/Cr, Glu/Cr, or Gln/Cr and either depression severity or lamotrigine treatment."	3.91	Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. ( Forester, BP; Harper, DG; Jensen, E; Mellen, EJ; Ravichandran, C; Silveri, M, 2019)
"Lamotrigine (LTG) has a good efficacy and tolerability as initial monotherapy for patients with newly diagnosed epilepsy (NDE)."	3.79	Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. ( Park, SP, 2013)
"Lamotrigine is an anticonvulsant and has an antiglutamatergic action, which may contribute to its antidepressant effects, since glutamate has been linked to depression."	3.78	Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. ( Abelaira, HM; Cipriano, AL; Quevedo, J; Réus, GZ; Ribeiro, KF; Scaini, G; Streck, EL; Zappellini, G, 2012)
"We describe a patient originally suffering from a depressive syndrome who developed Stevens-Johnson syndrome after 12 days of treatment with lamotrigine."	3.75	Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. ( Bertram, L; Grözinger, M; Liss, Y, 2009)
"Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy."	3.75	End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009)
"A 43-year-old woman was being treated with oxcarbazepine for depression and was started on lamotrigine 2 weeks prior to her presentation."	3.74	Lamotrigine-associated reversible severe hepatitis: a case report. ( Olson, KR; Su-Yin, AN; Tai, WW, 2008)
"We describe the case of a pregnancy healthy outcome after in utero consecutive exposure to lamotrigine and citalopram."	3.74	Consecutive exposure to lamotrigine and citalopram during pregnancy. ( Gentile, S; Vozzi, F, 2007)
"2 years) treated with the combination of lithium and lamotrigine were reviewed retrospectively for treatment response using the Clinical Global Impression-Bipolar Disorder-Improvement scale, divided into benefit for acute depressive symptoms, acute manic symptoms, and overall illness (including prophylaxis of mood episodes)."	3.73	Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. ( Berv, DA; Ghaemi, SN; Goodwin, FK; Klugman, J; Pardo, TB; Schrauwen, E; Shirzadi, AA, 2006)
"Any type of seizure can be observed in Alzheimer's disease (AD)."	2.58	Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2018)
"Levetiracetam was the drug of choice in treating patients with hepatic failure, or who have undergone organ transplantation."	2.55	Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017)
"Any type of seizure can be observed in Alzheimer's disease (AD)."	2.53	Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2016)
"The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%."	1.46	Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017)
"Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands."	1.43	Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016)
"Lamotrigine is an anticonvulsant drug that exhibits a clinical antidepressant effect."	1.33	Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. ( Andreatini, R; Consoni, FT; Vital, MA, 2006)
"Lamotrigine is an anticonvulsant with an efficacy profile in psychiatric disorders different from those of valproate, carbamazepine and gabapentine."	1.31	[Lamotrigine in the treatment of mental disorders]. ( Fladvad, T; Malt, UF, 2001)

Research

Studies (50)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

ADAS-cog in AD With Epileptiform Activity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (36.00)	29.6817
2010's	24 (48.00)	24.3611
2020's	8 (16.00)	2.80

Authors	Studies
Wilkowska, A	1
Wiglusz, MS	1
Jakuszkowiak-Wojten, K	1
Cubała, WJ	1
Joshi, A	1
Todd, S	1
Finn, DP	1
McClean, PL	1
Wong-Lin, K	1
Sharma, V	1
Yildiz, A	1
Siafis, S	1
Mavridis, D	1
Vieta, E	2
Leucht, S	1
Nikou, AF	1
Lai, M	1
Solmssen, C	1
Bhargava, M	1
Ben-David, K	1
Ramsubick, C	1
Rice, T	1
Coffey, B	1
Liu, J	3
Wang, LN	3
Peters, EM	1
Lodhi, RJ	1
Zhang, Y	2
Li, H	1
Balbuena, L	1
Hebel, T	1
Abdelnaim, MA	1
Deppe, M	1
Kreuzer, PM	1
Mohonko, A	1
Poeppl, TB	1
Rupprecht, R	1
Langguth, B	1
Schecklmann, M	1
Crawford, MJ	1
Sanatinia, R	1
Barrett, B	1
Cunningham, G	1
Dale, O	1
Ganguli, P	1
Lawrence-Smith, G	1
Leeson, VC	1
Lemonsky, F	1
Lykomitrou-Matthews, G	1
Montgomery, A	1
Morriss, R	1
Munjiza, J	1
Paton, C	1
Skorodzien, I	1
Singh, V	1
Tan, W	1
Tyrer, P	1
Reilly, JG	1
Simon, J	1
Geddes, JR	1
Gardiner, A	1
Rendell, J	1
Goodwin, GM	1
Mayer, S	1
Wu, LY	2
Wang, YP	2
Mellen, EJ	1
Harper, DG	1
Ravichandran, C	1
Jensen, E	1
Silveri, M	1
Forester, BP	1
Oya, K	1
Sakuma, K	1
Esumi, S	1
Hashimoto, Y	1
Hatano, M	1
Matsuda, Y	1
Matsui, Y	1
Miyake, N	1
Nomura, I	1
Okuya, M	1
Iwata, N	1
Kato, M	1
Hashimoto, R	1
Mishima, K	1
Watanabe, N	1
Kishi, T	1
Goh, KK	1
Chen, CH	1
Chiu, YH	1
Lu, ML	1
Park, SP	1
Reid, JG	1
Gitlin, MJ	1
Altshuler, LL	2
Friedman, AK	1
Walsh, JJ	1
Juarez, B	1
Ku, SM	1
Chaudhury, D	1
Wang, J	1
Li, X	1
Dietz, DM	1
Pan, N	1
Vialou, VF	1
Neve, RL	1
Yue, Z	1
Han, MH	1
Taylor, DM	1
Cornelius, V	1
Smith, L	1
Young, AH	1
Kowski, AB	1
Weissinger, F	1
Gaus, V	1
Fidzinski, P	1
Losch, F	1
Holtkamp, M	1
Alda, M	1
McKinnon, M	1
Blagdon, R	1
Garnham, J	1
MacLellan, S	1
O'Donovan, C	1
Hajek, T	1
Nair, C	1
Dursun, S	1
MacQueen, G	1
Solmi, M	1
Veronese, N	1
Zaninotto, L	1
van der Loos, ML	1
Gao, K	2
Schaffer, A	1
Reis, C	1
Normann, C	1
Anghelescu, IG	1
Correll, CU	1
Wieshmann, UC	1
Baker, G	1
Shih, JJ	1
Whitlock, JB	1
Chimato, N	1
Vargas, E	1
Karceski, SC	1
Frank, RD	1
Su-Yin, AN	1
Tai, WW	1
Olson, KR	1
Marino, SE	1
Meador, KJ	1
Loring, DW	1
Okun, MS	1
Fernandez, HH	1
Fessler, AJ	1
Kustra, RP	2
Miller, JM	1
Ray, PG	1
Roy, A	1
Schoenberg, MR	1
Vahle, VJ	1
Werz, MA	1
Mathew, SJ	2
Murrough, JW	1
aan het Rot, M	1
Collins, KA	1
Reich, DL	1
Charney, DS	1
Meltzer-Brody, SE	1
Zolnoun, D	1
Steege, JF	1
Rinaldi, KL	1
Leserman, J	1
Bertram, L	1
Liss, Y	1
Grözinger, M	1
Frey, LC	1
Strom, LA	1
Shrestha, A	1
Spitz, MC	1
Lebovits, A	1
Hainline, B	1
Stone, LS	1
Seminowicz, DA	1
Brunz, JT	1
Rosenquist, RW	1
Cowan, P	1
Li, N	1
He, X	1
Qi, X	1
He, S	1
Wang, Z	1
Kemp, DE	1
Chan, PK	1
Serrano, MB	1
Conroy, C	1
Fang, Y	1
Ganocy, SJ	1
Findling, RL	1
Calabrese, JR	3
Pavlovic, Z	1
Kato, H	1
Fukatsu, N	1
Noguchi, T	1
Oshima, T	1
Tadokoro, Y	1
Kanemoto, K	1
Abelaira, HM	1
Réus, GZ	1
Ribeiro, KF	1
Zappellini, G	1
Cipriano, AL	1
Scaini, G	1
Streck, EL	1
Quevedo, J	1
Anand, A	1
Gunn, AD	1
Barkay, G	1
Karne, HS	1
Nurnberger, JI	1
Ghosh, S	1
Brown, ES	1
Sunderajan, P	1
Hu, LT	1
Sowell, SM	1
Carmody, TJ	1
Consoni, FT	1
Vital, MA	1
Andreatini, R	1
Ghaemi, SN	1
Schrauwen, E	1
Klugman, J	1
Berv, DA	1
Shirzadi, AA	1
Pardo, TB	1
Goodwin, FK	1
Ettinger, AB	1
Hammer, AE	2
Kemp, S	1
Feely, M	1
Hay, A	1
Wild, H	1
Cooper, C	1
Fakhoury, TA	1
Barry, JJ	1
Mitchell Miller, J	1
Vuong, A	1
Frye, MA	2
Yatham, LN	1
Bowden, CL	1
Ketter, TA	1
Suppes, T	2
Adams, BE	1
Thompson, TR	1
Cruz, N	1
Sánchez-Moreno, J	1
Muzina, DJ	1
Colangelo, E	1
Manning, JS	1
Krupitsky, EM	1
Rudenko, AA	1
Burakov, AM	1
Slavina, TY	1
Grinenko, AA	1
Pittman, B	1
Gueorguieva, R	1
Petrakis, IL	1
Zvartau, EE	1
Krystal, JH	1
Gentile, S	1
Vozzi, F	1
Kelly, DI	1
Keck, PE	1
McElroy, SL	1
Mintz, J	1
Nolen, WA	1
Luckenbaugh, DA	1
Post, RM	1
Leverich, GS	1
Kupka, RW	1
Grunze, H	1
Malt, UF	1
Fladvad, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study[NCT03489044]	Phase 2	30 participants (Anticipated)	Interventional	2018-10-28	Active, not recruiting
Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819]	Phase 2	34 participants (Actual)	Interventional	2014-10-16	Completed
Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder[NCT00214877]	Phase 3	40 participants (Anticipated)	Interventional	2003-11-30	Completed
The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822]		550 participants (Anticipated)	Observational	2022-02-18	Recruiting
Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression[NCT00419003]	Phase 4	26 participants (Actual)	Interventional	2006-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Blood Serum Prolactin Level

Intervention	score on a scale (Mean)
Levetiracetam (Epileptiform Activity)	-1.0
Placebo (Epileptiform Activity)	1.5

Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in ADAS-cog

Intervention	ng/mL (Mean)
Levetiracetam	0.1
Placebo	0.2

Changes in Behavior and Level of Disability - ADCS-ADL

Intervention	score on a scale (Mean)
Levetiracetam	-0.2
Placebo	0.8

Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in Behavior and Level of Disability - ADCS-CGIC

Intervention	score on a scale (Mean)
Levetiracetam	0.4
Placebo	0.3

ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in Behavior and Level of Disability - Neuropsychiatric Inventory (NPI)

Intervention	score on a scale (Mean)
Levetiracetam	4.0
Placebo	4.0

Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in Cognitive Function as Measured by a Virtual Route Learning Test

Intervention	score on a scale (Mean)
Levetiracetam	-0.8
Placebo	0.2

A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in Epileptiform Events

Intervention	correct turns (Mean)
No Epileptiform Activity	-6.0
Epileptic Activity	17.4

"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in Executive Function as Measured by the NIH EXAMINER Computer Battery

Intervention	Epileptiform events (Mean)
Levetiracetam	-0.1
Placebo	-0.2

Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Changes in Stroop Interference Naming

Intervention	score on a scale (Mean)
Levetiracetam	-0.06
Placebo	-0.14

Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Clinical Dementia Rating Sum of Boxes (CDR-SOB)

Intervention	score on a scale (Mean)
Levetiracetam	1.5
Placebo	-1.4

Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

NIH EXAMINER in AD With Epileptiform Activity

Intervention	score on a scale (Mean)
Levetiracetam	0.1
Placebo	0.1

Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Standardized Assessments of Clinical Fluctuations - One Day Fluctuation Assessment Scale

Intervention	score on a scale (Mean)
No Epileptiform Activity	-0.01
Epileptiform Activity	0.22

The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Standardized Assessments of Clinical Fluctuations -The Clinician Assessment of Fluctuation

Intervention	score on a scale (Mean)
Levetiracetam	0.3
Placebo	-0.4

Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Stroop Interference in AD With Epileptiform Activity

Intervention	score on a scale (Mean)
Levetiracetam	0.9
Placebo	0.1

Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)

Montgomery-Asberg Depression Rating Scale (MARDS) Score (Acute Response to IV Ketamine in Patients With Treatment Resistant Major Depression)

Intervention	score on a scale (Mean)
Levetiracetam (Epileptiform Activity)	4.7
Placebo (Epileptiform Activity)	-2.6

Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. The primary outcome for the initial phase of the trial was the 24-h MADRS score, which included all 10 MADRS items. (NCT00419003)
Timeframe: 24 Hours

Intervention	scores on a scale (Mean)
Riluzole Group	24.4
Placebo	22.0

Article	Year
Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review. Cells, 2022, 02-12, Volume: 11, Issue:4 Topics: Animals; Antidepressive Agents; Depression; Humans; Ketamine; Lamotrigine; Psychopharmacology	2022
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. The lancet. Psychiatry, 2023, Volume: 10, Issue:9 Topics: Adult; Bipolar Disorder; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxe	2023
Treatment of epilepsy for people with Alzheimer's disease. The Cochrane database of systematic reviews, 2021, 05-11, Volume: 5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female	2021
Treatment of epilepsy for people with Alzheimer's disease. The Cochrane database of systematic reviews, 2021, 05-11, Volume: 5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female	2021
Treatment of epilepsy for people with Alzheimer's disease. The Cochrane database of systematic reviews, 2021, 05-11, Volume: 5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female	2021
Treatment of epilepsy for people with Alzheimer's disease. The Cochrane database of systematic reviews, 2021, 05-11, Volume: 5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female	2021
Treatment of epilepsy for people with Alzheimer's disease. The Cochrane database of systematic reviews, 2018, 12-20, Volume: 12 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female	2018
Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacology reports, 2019, Volume: 39, Issue:3 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depression; Double-Blind Method; Female; Humans; Lamo	2019
Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety. Journal of psychopharmacology (Oxford, England), 2019, Volume: 33, Issue:6 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Met	2019
Lamotrigine in psychiatric disorders. The Journal of clinical psychiatry, 2013, Volume: 74, Issue:7 Topics: Anticonvulsants; Depression; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Epidemi	2013
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta psychiatrica Scandinavica, 2014, Volume: 130, Issue:6 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder;	2014
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS spectrums, 2016, Volume: 21, Issue:5 Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip	2016
Treatment of epilepsy for people with Alzheimer's disease. The Cochrane database of systematic reviews, 2016, 11-02, Volume: 11 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female	2016
Epilepsy treatment in adults and adolescents: Expert opinion, 2016. Epilepsy & behavior : E&B, 2017, Volume: 69 Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru	2017
Differentiating bipolar disorder from depression in primary care. Cleveland Clinic journal of medicine, 2007, Volume: 74, Issue:2 Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Diagnosis, Differential; Humans; Lamotrigi	2007

Article	Year
Lamotrigine for people with borderline personality disorder: a RCT. Health technology assessment (Winchester, England), 2018, Volume: 22, Issue:17 Topics: Adult; Antipsychotic Agents; Borderline Personality Disorder; Cost-Benefit Analysis; Depression; Dou	2018
Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). Bipolar disorders, 2018, Volume: 20, Issue:8 Topics: Antipsychotic Agents; Bipolar Disorder; Cost-Benefit Analysis; Depression; Double-Blind Method; Drug	2018
Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. The British journal of psychiatry : the journal of mental science, 2017, Volume: 210, Issue:1 Topics: Adult; Anxiety; Bipolar Disorder; Cognitive Dysfunction; Cross-Over Studies; Depression; Double-Blin	2017
Subjective perception of cognition is related to mood and not performance. Epilepsy & behavior : E&B, 2009, Volume: 14, Issue:3 Topics: Adult; Affect; Anticonvulsants; Cognition; Cross-Over Studies; Depression; Double-Blind Method; Epil	2009
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:1 Topics: Adult; Aged; Depression; Drug Interactions; Drug Resistance; Excitatory Amino Acid Antagonists; Fema	2010
Open-label trial of lamotrigine focusing on efficacy in vulvodynia. The Journal of reproductive medicine, 2009, Volume: 54, Issue:3 Topics: Adult; Aged; Analgesics; Anxiety; Comorbidity; Depression; Dose-Response Relationship, Drug; Female;	2009
Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. Psychopharmacology bulletin, 2010, Volume: 43, Issue:4 Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Depression	2010
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar disorders, 2012, Volume: 14, Issue:1 Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depression; Dopamine Agents; Doubl	2012
A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:11 Topics: Adolescent; Adult; Aged; Bipolar Disorder; Calcium Channel Blockers; Cocaine-Related Disorders; Depr	2012
Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy & behavior : E&B, 2007, Volume: 10, Issue:1 Topics: Adult; Affect; Analysis of Variance; Anticonvulsants; Depression; Double-Blind Method; Epilepsy; Fem	2007
Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy & behavior : E&B, 2007, Volume: 10, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Depression; Drug Evaluation; Epilepsy;	2007
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:4 Topics: Adult; Alcoholism; Arousal; Autonomic Nervous System; Depression; Diazepam; Excitatory Amino Acid An	2007

Article	Year
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. BMC medical informatics and decision making, 2022, 10-07, Volume: 22, Issue:1 Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin	2022
Development of Posttraumatic Stress Disorder During Treatment of Depression With Lamotrigine. The primary care companion for CNS disorders, 2022, 11-01, Volume: 24, Issue:6 Topics: Anticonvulsants; Depression; Humans; Lamotrigine; Stress Disorders, Post-Traumatic; Triazines	2022
Topiramate for Posttraumatic Symptoms in an Obese Adolescent Girl. Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:3 Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Anticonvulsants; Antipsychotic Agents; Depression;	2021
Lamotrigine for acute bipolar depression: An exploratory item-level analysis. Brain and behavior, 2021, Volume: 11, Issue:8 Topics: Adult; Bipolar Disorder; Depression; Double-Blind Method; Humans; Lamotrigine; Psychiatric Status Ra	2021
Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs. European archives of psychiatry and clinical neuroscience, 2021, Volume: 271, Issue:7 Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Humans; Lamotrigine; Lithi	2021
Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2019, Volume: 27, Issue:8 Topics: Aged; Aging; Antipsychotic Agents; Aspartic Acid; Biomarkers; Bipolar Disorder; Cerebral Cortex; Cre	2019
Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. Epilepsy & behavior : E&B, 2013, Volume: 28, Issue:1 Topics: Adolescent; Adult; Aged; Anticonvulsants; Depression; Epilepsy; Exanthema; Female; Humans; Lamotrigi	2013
Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. Science (New York, N.Y.), 2014, Apr-18, Volume: 344, Issue:6181 Topics: Animals; Behavior, Animal; Depression; Dopaminergic Neurons; Electrophysiological Phenomena; Homeost	2014
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. Epilepsy & behavior : E&B, 2016, Volume: 54 Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve	2016
Efficacy and tolerability of anti-epileptic drugs-an internet study. Acta neurologica Scandinavica, 2017, Volume: 135, Issue:5 Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine;	2017
Lamotrigine-associated reversible severe hepatitis: a case report. Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2008, Volume: 4, Issue:4 Topics: Adult; Anticonvulsants; Antimanic Agents; Carbamazepine; Chemical and Drug Induced Liver Injury; Dep	2008
Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case. Acta dermato-venereologica, 2009, Volume: 89, Issue:3 Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Biopsy; C-Reactive Protein; Depression; Drug Ther	2009
End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. Epilepsy & behavior : E&B, 2009, Volume: 15, Issue:4 Topics: Adult; Affective Symptoms; Agoraphobia; Anticonvulsants; Bipolar Disorder; Depression; Epilepsy; Fem	2009
Struck from behind: maintaining quality of life with chronic low back pain. The journal of pain, 2009, Volume: 10, Issue:9 Topics: Accidents, Traffic; Activities of Daily Living; Adult; Analgesics, Opioid; Bupropion; Depression; Do	2009
The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:12 Topics: Animals; Anticonvulsants; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor	2010
Lamotrigine reduces craving and depressive symptoms in cocaine dependence. The Journal of neuropsychiatry and clinical neurosciences, 2011,Winter, Volume: 23, Issue:1 Topics: Behavior, Addictive; Cocaine-Related Disorders; Depression; Humans; Lamotrigine; Triazines	2011
Lamotrigine improves aggression in patients with temporal lobe epilepsy. Epilepsy & behavior : E&B, 2011, Volume: 21, Issue:2 Topics: Adult; Aggression; Anticonvulsants; Depression; Epilepsy, Temporal Lobe; Female; Humans; Lamotrigine	2011
Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. Pharmacology, biochemistry, and behavior, 2012, Volume: 101, Issue:3 Topics: Amygdala; Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor	2012
Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:6 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biogenic Monoamines; Depression; Lamot	2006
Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. Journal of psychiatric practice, 2006, Volume: 12, Issue:5 Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Depression; Drug Therapy, Combination; Female;	2006
Psychological factors and use of antiepileptic drugs: pilot work using an objective measure of adherence. Psychology, health & medicine, 2007, Volume: 12, Issue:1 Topics: Adolescent; Adult; Aged; Anticonvulsants; Anxiety; Culture; Depression; Drug Monitoring; Drug Therap	2007
Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11 Topics: Adult; Antimanic Agents; Bipolar Disorder; Comorbidity; Depression; Humans; Incidence; Lamotrigine;	2006
[Vigency of lithium treatment]. Medicina clinica, 2007, Jan-13, Volume: 128, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Controlled Clinical Trials as Topic; Depres	2007
Consecutive exposure to lamotrigine and citalopram during pregnancy. Archives of women's mental health, 2007, Volume: 10, Issue:6 Topics: Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Drug Administration Sched	2007
Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network. International clinical psychopharmacology, 2007, Volume: 22, Issue:6 Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Databases, Factual; Depression; Dib	2007
[Lamotrigine in the treatment of mental disorders]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2001, May-10, Volume: 121, Issue:12 Topics: Adolescent; Adult; Aged; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Depression; Femal	2001

lamotrigine and Depression